Sophiris Bio Inc.
(NASDAQ : SPHS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.09%105.071.1%$1270.33m
GILDGilead Sciences, Inc.
0.12%72.910.9%$642.37m
AMGNAmgen Inc.
0.31%170.491.1%$479.44m
REGNRegeneron Pharmaceuticals, Inc.
0.96%391.272.7%$362.55m
BIIBBiogen Inc.
-0.48%308.321.2%$348.13m
ALXNAlexion Pharmaceuticals, Inc.
0.85%108.511.9%$268.90m
VRTXVertex Pharmaceuticals Incorporated
-0.07%146.941.9%$232.57m
ALNYAlnylam Pharmaceuticals, Inc
0.87%133.4810.0%$194.84m
INCYIncyte Corporation
0.36%99.362.5%$179.89m
NKTRNektar Therapeutics
-2.71%48.406.1%$171.79m
ILMNIllumina, Inc.
-0.10%215.133.5%$154.37m
JUNOJuno Therapeutics, Inc.
1.88%61.4613.5%$140.20m
AAgilent Technologies, Inc.
0.54%69.061.5%$132.37m
SRPTSarepta Therapeutics, Inc.
0.18%56.3216.8%$115.83m
BLUEBluebird Bio, Inc.
0.70%168.3817.2%$115.23m

Company Profile

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which develops products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by Jim L. Heppell in May 2003 and is headquartered in La Jolla, CA.